689,655 Shares in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Purchased by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. purchased a new stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Free Report) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 689,655 shares of the company's stock, valued at approximately $9,607,000. Frazier Life Sciences Management L.P. owned approximately 0.68% of Day One Biopharmaceuticals as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DAWN. Mirae Asset Global Investments Co. Ltd. boosted its stake in Day One Biopharmaceuticals by 38.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company's stock valued at $51,000 after purchasing an additional 1,002 shares in the last quarter. Quest Partners LLC boosted its stake in Day One Biopharmaceuticals by 9,238.6% during the 3rd quarter. Quest Partners LLC now owns 7,751 shares of the company's stock valued at $108,000 after purchasing an additional 7,668 shares in the last quarter. SG Americas Securities LLC bought a new position in Day One Biopharmaceuticals during the 2nd quarter valued at $113,000. Point72 DIFC Ltd bought a new position in Day One Biopharmaceuticals during the 2nd quarter valued at $124,000. Finally, Hsbc Holdings PLC bought a new stake in shares of Day One Biopharmaceuticals during the 2nd quarter worth $163,000. 87.95% of the stock is owned by institutional investors.

Day One Biopharmaceuticals Stock Down 1.9 %

Shares of DAWN traded down $0.25 during mid-day trading on Tuesday, reaching $13.22. The company's stock had a trading volume of 1,040,061 shares, compared to its average volume of 959,979. The business has a fifty day moving average of $14.24 and a 200 day moving average of $14.06. The company has a market cap of $1.33 billion, a price-to-earnings ratio of -12.83 and a beta of -1.51. Day One Biopharmaceuticals, Inc. has a 1 year low of $11.51 and a 1 year high of $18.07.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last released its earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.58. The business had revenue of $93.76 million during the quarter, compared to analysts' expectations of $15.05 million. During the same quarter in the previous year, the company earned ($0.54) EPS. On average, analysts predict that Day One Biopharmaceuticals, Inc. will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. HC Wainwright reissued a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. TD Cowen raised Day One Biopharmaceuticals to a "strong-buy" rating in a research note on Monday, November 4th. Finally, Needham & Company LLC reissued a "buy" rating and set a $33.00 price objective on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $35.71.

Insider Buying and Selling

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 10,000 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $16.10, for a total transaction of $161,000.00. Following the transaction, the insider now directly owns 1,057,535 shares of the company's stock, valued at $17,026,313.50. This represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders sold 21,745 shares of company stock worth $349,267. Corporate insiders own 8.40% of the company's stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.